In wake of David Tuller’s investigation, PACE investigators publish follow up study Last week, journalist David Tuller published a four-part investigative piece on the 2011 PACE trial, a £5 million (US$8 million) non-blind study of cognitive behavioral therapy (CBT) and graded exercise (GET) as treatment for chronic fatigue syndrome. In his piece, Tuller quotes top
Journalist and public health expert David Tuller completed yesterday the publication of his highly critical investigation into the UK’s £5 million PACE trial, on the well known Virology Blog (see Parts 1 and 2, Part 3 and Part 4). The PACE trial was a non-blind study of cognitive behaviour therapy (CBT) and graded exercise therapy (GET)
Health scientist and New York Times published journalist David Tuller today launched a damning critique upon the UK’s £5 million PACE trial in an article published on the popular Virology Blog. The PACE trial was an open-label study of graded exercise therapy and cognitive behavioural therapy for chronic fatigue syndrome that used subjective measures as
In the US? Find your state and sign the petition. Not in the US? Sign the global solidarity petition. Share your story, tell congress why we need Mylagic Encephalomyelitis Funding Equality.
UK CMRC conference to be livestreamed on 13 and 14 October Parts of this year’s UK CFS/ME Research Collaborative (CMRC) international conference, which will be held in Newcastle on Tuesday the 13th and Wednesday the 14th of October, will be livestreamed by the charity Action for ME. The conference has a full two-day agenda of
A new German study published in Brain, Behavior, and Immunity by Loebel, et al. has found that Chronic Fatigue Syndrome* may be an infection-triggered autoimmune disease, at least in a subset of patients studied. Samples from a large cohort (n=268) in Berlin and a smaller sample of patients treated with Rituximab (n=25) were measured against controls (n=168).
Hemispherx Biopharma research shows that CFS patients who can perform more than 9 minutes on a treadmill are more likely to benefit from Ampligen.
New Australian study shows immune difference in moderate and severe patients. It may lead to a test based on these markers.
The UK CFS/ME Research Collaborative People with M.E. need better treatment and support. This can only be achieved through increasing the quality of research; by coordinating a stronger collaborative approach to stimulate more research through bringing in expertise from outside the field and supporting early stage career researchers; and by working strategically to increase funding
AIDS Research took a death sentence and made it a manageable disease. ME-CFS needs the same level of effort to solve this worse disease that often is lifelong. Request $250M per year for ME-CFS R&D, so NIH can stop discrimination against ME-CFS and related diseases.
